Regentis Biomaterials Ltd.

www.regentis.co.il

High-Tech Company

Graduated from: TechnionSeed

TECH VERTICALS

Healthtech, Implants, Life Sciences, Medical Devices, MedTech, Nanotechnology, Orthopedics

General Data

Sector	Medical Devices
Company Stage:	Initial Revenues
Established	2004
Number of Employees	3
Reg. Number:	abCDe

DESCRIPTION

Regentis Biomaterials is a global biomaterials company dedicated to developing groundbreaking tissue repair solutions that restore the health and quality of life of patients. The company’s current efforts are focused on orthopedic treatments using degradable hydrogel implants to regenerate damaged or diseased tissue. Gelrin© is the regenerative hydrogel platform for all product development. The company’s first commercial product is GelrinC©, a cell-free, off-the-shelf hydrogel implant for the treatment of painful injuries to articular knee cartilage. This cost-effective treatment offers orthopedic surgeons a simple to perform procedure while providing patients with sustained pain relief and function improvement.

TECHNOLOGY

Gelrin is a unique hydrogel platform composed of polyethylene glycol diacrylate (PEG-DA) and denatured fibrinogen. The PEG-DA produces a dense hydrogel network that is impermeable to cells while the denatured fibrinogen provides cleavage sites for enzymatic degradation. The mechanism of degradation is primarily by controlled surface erosion. This patented technology has potential as a development platform to address diverse clinical treatments for patients.

Products and Phases

Product	Phase
GelrinC	CE Approved
GelrinC®, is a biodegradable hydrogel implant for the treatment of painful injuries to cartilage. The hydrogelIs applied as a liquid to a cartilage defect. After a short, 90-second exposure to ultraviolet light, the hydrogel turns into an elastomeric implant tightly integrated with surrounding tissue. The GelrinC implant degrades within 6-12 months and is replaced by newly regenerated tissue.

	TARGET MARKETS
	Hospitals, Orthopedic Surgeons, Orthopedic Companies, Pharmaceutical Companies

	BUSINESS MODEL
	B2B

SERVICE PROVIDERS

Company Name	Type
abC Defghij	Patent Attorneys
abC Defghij	Accounting Firm
abC Defghij	Law Firm

CONTACT INFO

Expand / Collapse All

Main Address: Or Akiva, Israel

Address	12 Hailan St., Northern Industrial Zone
POB	260
City	Or Akiva
Country	Israel
Zip	3060000

Contact Person	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

Branch Address: Herzliya, Israel

Address	60, Medinat Hyahudim Entrance C
City	Herzliya
Country	Israel
Zip	4676652

Contact Person	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

Branch Address: Princeton, United States

City	Princeton
State/Province	NJ
Country	United States

Contact Person	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

	MANAGEMENT

Key Executive

Name	Title	Previous Position
Prof. Eli Hazum	CEO	Yeda R&D (Head of the Innovation Development, Enhancement & Acceleration program (IDEA))
Mr. Arie Gordashnikov	CFO
Dr. Dror Seliktar	CSO & Co-Founder
Mr. Yehiel Tal	Co-Founder	ProChon (VP, Product & Business Development)

	BOARD

Board

Member	Title	Affiliation
abC Defghij	Chairman	Founder & Managing Partner, Medica Venture Partners
abC Defghij	Board Member	Managing Partner, SCP Vitalife
abC Defghij	Board Member	CEO, Laser Team Medical
abC Defghij	Board Member	Principal, SFADC
abC Defghij	Board Member	President & CEO & Director at SeaSpine

	FINANCIAL ROUNDS

Total Capital Raised
abCDe

Financial Rounds

Numbers of Investors

Expand / Collapse All

Round

Date

Stage

Amount

Valuation

Fourth Round

Feb. 07, 2016

Initial Revenues

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Technology Transfer Company	abCDe
abC Defghij	High-Tech Company	abCDe

Third Round

May. 16, 2012

R&D

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Corporate VC	abCDe

Second Round

May. 01, 2009

R&D

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Venture Capital Fund	abCDe

First Round

Aug. 16, 2007

R&D

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Venture Capital Fund	abCDe	Holds 0.42% of the company
abC Defghij	Venture Capital Fund	abCDe

Seed - Extended

Jun. 01, 2006

Seed

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Venture Capital Fund	abCDe

Seed

Oct. 25, 2004

Seed

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Technology Transfer Company	abCDe
abC Defghij	Government Agency	abCDe	R&D Grant
abC Defghij	Incubator	abCDe

	R&D Grants

Expand / Collapse All

Round

Date

Stage

Amount

Remarks

R&D Grant

Jun. 01, 2019

Initial Revenues

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Government Agency	abCDe

R&D Grant

Jun. 01, 2018

Initial Revenues

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij*	Government Agency	abCDe

Last Updated:	abCDe
IVC Number:	abCDe